Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2024-12-30 Report Publication Anno…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-12-30 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-12-30 English
PROXY FORM FOR USE AT THE 2025 FIRST EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a proxy form for use at the 2025 first extraordinary general meeting, providing instructions and proxy appointment for shareholder voting. This falls under materials sent to shareholders to solicit votes and provide information for a meeting, matching the Proxy Solicitation & Information Statement category.
2024-12-23 English
NOTICE OF 2025 FIRST EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice convening the 2025 first Extraordinary General Meeting (EGM) of RemeGen Co., Ltd., setting out the meeting date, venue, resolution to be voted on, and proxy appointment procedures. It is addressed to shareholders to solicit their votes and attendance at the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), as it is not reporting results but providing meeting notice and voting instructions.
2024-12-23 English
PROPOSED APPOINTMENT OF NEW INDEPENDENT NON-EXECUTIVE DIRECTOR AND NOTICE OF 2025 FIRST EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a shareholder circular issued in connection with the company’s extraordinary general meeting. It includes a "Notice of EGM," detailed background on a proposed resolution (appointment of a new independent non-executive director), a letter from the Board, definitions, and proxy voting instructions. This type of communication is sent to shareholders to solicit their votes and provide full information to enable informed voting decisions. It matches the description of "Proxy Solicitation & Information Statement (Code: PSI)."
2024-12-23 English
PROPOSED APPOINTMENT OF NEW INDEPENDENT NON-EXECUTIVE DIRECTOR
Board/Management Information Classification · 95% confidence The document is a formal stock exchange announcement regarding the proposed appointment of a new independent non-executive director (Mr. Huang) and related committee positions. It details board resolutions, candidate biography, service contract terms, and upcoming EGM for shareholder approval. This clearly falls under announcements of changes in the company's board of directors, matching the Board/Management Information category.
2024-12-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.